Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1947 1
1949 1
1950 2
1958 2
1960 3
1964 2
1965 1
1966 2
1967 1
1968 2
1970 2
1974 1
1975 1
1978 3
1979 1
1980 2
1985 2
1986 4
1987 1
1988 2
1989 1
1990 4
1991 3
1992 8
1993 17
1994 11
1995 4
1996 7
1997 11
1998 12
1999 14
2000 17
2001 18
2002 13
2003 13
2004 17
2005 26
2006 26
2007 29
2008 37
2009 36
2010 57
2011 77
2012 74
2013 96
2014 112
2015 112
2016 119
2017 126
2018 141
2019 145
2020 169
2021 181
2022 177
2023 189
2024 56

Text availability

Article attribute

Article type

Publication date

Search Results

1,984 results

Results by year

Filters applied: . Clear all
Page 1
Survival with Cemiplimab in Recurrent Cervical Cancer.
Tewari KS, Monk BJ, Vergote I, Miller A, de Melo AC, Kim HS, Kim YM, Lisyanskaya A, Samouëlian V, Lorusso D, Damian F, Chang CL, Gotovkin EA, Takahashi S, Ramone D, Pikiel J, Maćkowiak-Matejczyk B, Guerra Alía EM, Colombo N, Makarova Y, Rischin D, Lheureux S, Hasegawa K, Fujiwara K, Li J, Jamil S, Jankovic V, Chen CI, Seebach F, Weinreich DM, Yancopoulos GD, Lowy I, Mathias M, Fury MG, Oaknin A; Investigators for GOG Protocol 3016 and ENGOT Protocol En-Cx9. Tewari KS, et al. Among authors: de melo ac. N Engl J Med. 2022 Feb 10;386(6):544-555. doi: 10.1056/NEJMoa2112187. N Engl J Med. 2022. PMID: 35139273 Clinical Trial.
Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, Lee JY, Thomes Pepin J, Sundborg M, Shai A, de la Garza J, Nishio S, Gold MA, Wang K, McIntyre K, Tillmanns TD, Blank SV, Liu JH, McCollum M, Contreras Mejia F, Nishikawa T, Pennington K, Novak Z, De Melo AC, Sehouli J, Klasa-Mazurkiewicz D, Papadimitriou C, Gil-Martin M, Brasiuniene B, Donnelly C, Del Rosario PM, Liu X, Van Nieuwenhuysen E; DUO-E Investigators. Westin SN, et al. Among authors: de melo ac. J Clin Oncol. 2024 Jan 20;42(3):283-299. doi: 10.1200/JCO.23.02132. Epub 2023 Oct 21. J Clin Oncol. 2024. PMID: 37864337 Free PMC article. Clinical Trial.
Frailty syndrome and risks for falling in the elderly community.
Taguchi CK, Menezes PL, Melo ACS, Santana LS, Conceição WRS, Souza GF, Araújo BCL, Silva ARD. Taguchi CK, et al. Among authors: melo acs. Codas. 2022 Aug 8;34(6):e20210025. doi: 10.1590/2317-1782/20212021025pt. eCollection 2022. Codas. 2022. PMID: 35946721 Free PMC article.
Comparative host-coronavirus protein interaction networks reveal pan-viral disease mechanisms.
Gordon DE, Hiatt J, Bouhaddou M, Rezelj VV, Ulferts S, Braberg H, Jureka AS, Obernier K, Guo JZ, Batra J, Kaake RM, Weckstein AR, Owens TW, Gupta M, Pourmal S, Titus EW, Cakir M, Soucheray M, McGregor M, Cakir Z, Jang G, O'Meara MJ, Tummino TA, Zhang Z, Foussard H, Rojc A, Zhou Y, Kuchenov D, Hüttenhain R, Xu J, Eckhardt M, Swaney DL, Fabius JM, Ummadi M, Tutuncuoglu B, Rathore U, Modak M, Haas P, Haas KM, Naing ZZC, Pulido EH, Shi Y, Barrio-Hernandez I, Memon D, Petsalaki E, Dunham A, Marrero MC, Burke D, Koh C, Vallet T, Silvas JA, Azumaya CM, Billesbølle C, Brilot AF, Campbell MG, Diallo A, Dickinson MS, Diwanji D, Herrera N, Hoppe N, Kratochvil HT, Liu Y, Merz GE, Moritz M, Nguyen HC, Nowotny C, Puchades C, Rizo AN, Schulze-Gahmen U, Smith AM, Sun M, Young ID, Zhao J, Asarnow D, Biel J, Bowen A, Braxton JR, Chen J, Chio CM, Chio US, Deshpande I, Doan L, Faust B, Flores S, Jin M, Kim K, Lam VL, Li F, Li J, Li YL, Li Y, Liu X, Lo M, Lopez KE, Melo AA, Moss FR 3rd, Nguyen P, Paulino J, Pawar KI, Peters JK, Pospiech TH Jr, Safari M, Sangwan S, Schaefer K, Thomas PV, Thwin AC, Trenker R, Tse E, Tsui TKM, Wang F, Whitis N, Yu Z, Zhang K, Zhang Y, Zhou F, Saltzberg D; QCRG Str… See abstract for full author list ➔ Gordon DE, et al. Among authors: melo aa. Science. 2020 Dec 4;370(6521):eabe9403. doi: 10.1126/science.abe9403. Epub 2020 Oct 15. Science. 2020. PMID: 33060197 Free PMC article.
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial.
Kristeleit R, Lisyanskaya A, Fedenko A, Dvorkin M, de Melo AC, Shparyk Y, Rakhmatullina I, Bondarenko I, Colombo N, Svintsitskiy V, Biela L, Nechaeva M, Lorusso D, Scambia G, Cibula D, Póka R, Oaknin A, Safra T, Mackowiak-Matejczyk B, Ma L, Thomas D, Lin KK, McLachlan K, Goble S, Oza AM. Kristeleit R, et al. Among authors: de melo ac. Lancet Oncol. 2022 Apr;23(4):465-478. doi: 10.1016/S1470-2045(22)00122-X. Epub 2022 Mar 14. Lancet Oncol. 2022. PMID: 35298906 Clinical Trial.
A brazilian nationwide multicenter study on deficiency of deaminase-2 (DADA2).
Melo A, de Carvalho LM, Ferriani VPL, Cavalcanti A, Appenzeller S, Oliveira VR, Neto HC, Rosário NA, de Oliveira Poswar F, Guimaraes MX, Kokron CM, Maia RE, Silva GD, Keller G, Ferreira MD, Vasconcelos DM, Toledo-Barros MAM, Barros SF, Neto NSR, Krieger MH, Kalil J, Mendonça LO. Melo A, et al. Adv Rheumatol. 2023 May 22;63(1):23. doi: 10.1186/s42358-023-00303-5. Adv Rheumatol. 2023. PMID: 37217999
Implementation of a pharmacogenomic program in a Brazilian public institution.
Suarez-Kurtz G, Kovaleski G, Elias AB, Motta V, Wolch K, Emerenciano M, Mansur MB, Palladino AM, Accioly MT, Ferreira M, Gonçalves AA, de Melo AC. Suarez-Kurtz G, et al. Among authors: de melo ac. Pharmacogenomics. 2020 Jun;21(8):549-557. doi: 10.2217/pgs-2020-0016. Epub 2020 May 7. Pharmacogenomics. 2020. PMID: 32378980 Review.
Platynosomum illiciens.
Pinto HA, Melo AL, Mati VLT. Pinto HA, et al. Among authors: melo al. Trends Parasitol. 2022 Feb;38(2):188-189. doi: 10.1016/j.pt.2021.08.004. Epub 2021 Sep 1. Trends Parasitol. 2022. PMID: 34481739 No abstract available.
1,984 results